Cargando…
Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
With the current widespread use of dolutegravir in low-income countries, the understanding of the impact of nucleoside reverse transcriptase inhibitor (NRTI-) associated mutations on the efficacy of dolutegravir-containing antiretroviral therapy (ART) is of utmost importance. We describe a rare case...
Autores principales: | Braun, Dominique L., Scheier, Thomas, Ledermann, Ulrich, Flepp, Markus, Metzner, Karin J., Böni, Jürg, Günthard, Huldrych F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699495/ https://www.ncbi.nlm.nih.gov/pubmed/33228206 http://dx.doi.org/10.3390/v12111330 |
Ejemplares similares
-
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019) -
Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019) -
Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022) -
Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial
por: West, Emily, et al.
Publicado: (2023) -
Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)